FARN — Faron Pharmaceuticals Oy Share News
0.000.00%
- £139.15m
- £144.40m
REG - Faron Pharma. Oy - Positive FDA Feedback to Progress Bexmarilimab
AnnouncementREG - Faron Pharma. Oy - Notice of Faron Pharmaceuticals Ltd’s AGM
AnnouncementREG - Faron Pharma. Oy - Faron´s Annual Report 2022 Published
AnnouncementREG - Faron Pharma. Oy - Financial Statement January 1 to December 31 2022
AnnouncementREG - Faron Pharma. Oy - Update to Faron’s Financial Calendar for 2023
AnnouncementRCS - Faron Pharma. Oy - Notice of 2022 Full-Year Results and Annual Report
AnnouncementREG - Faron Pharma. Oy - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 31/01/2023
AnnouncementREG - Faron Pharma. Oy - Holding(s) in Company
AnnouncementREG - Faron Pharma. Oy - Results of Placing
AnnouncementREG - Faron Pharma. Oy - Proposed Issue and Placing
AnnouncementREG - Faron Pharma. Oy - Price Monitoring Extension
AnnouncementREG - Faron Pharma. Oy - Price Monitoring Extension
AnnouncementREG - Faron Pharma. Oy - Second Price Monitoring Extn
AnnouncementREG - Faron Pharma. Oy - Title: BEXMAB study update
AnnouncementREG - Faron Pharma. Oy - Faron’s Financial Calendar for 2023
AnnouncementREG - Faron Pharma. Oy - BEXMAB Study Update
AnnouncementREG - Faron Pharma. Oy - Faron Appoints Maija Hollmén PhD as CSO
AnnouncementREG - Faron Pharma. Oy - Amendment Terms and Conditions with IPF Partners
Announcement